Tyra Biosciences (NASDAQ:TYRA) Price Target Cut to $27.00 by Analysts at HC Wainwright

Tyra Biosciences (NASDAQ:TYRA) had its price target decreased by HC Wainwright from $29.00 to $27.00 in a research report report published on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

TYRA has been the subject of a number of other reports. Wedbush reaffirmed an “outperform” rating and issued a $53.00 target price on shares of Tyra Biosciences in a report on Thursday, September 10th. Oppenheimer reissued an “outperform” rating and set a $40.00 price target (down from $50.00) on shares of Tyra Biosciences in a research note on Tuesday, September 22nd. Jefferies Financial Group restated a “buy” rating and issued a $42.00 price target on shares of Tyra Biosciences in a report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Thursday, October 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tyra Biosciences in a research note on Thursday, September 10th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Tyra Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $47.40.

Tyra Biosciences Trading Down 0.1%

Shares of TYRA opened at $20.97 on Wednesday. The company has a 50-day simple moving average of $21.95 and a 200-day simple moving average of $29.49. Tyra Biosciences has a 52-week low of $14.67 and a 52-week high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.07). As a group, research analysts anticipate that Tyra Biosciences will post -2.68 EPS for the current year.

Hedge Funds Weigh In On Tyra Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC lifted its holdings in shares of Tyra Biosciences by 843.4% in the third quarter. Sterling Capital Management LLC now owns 1,217 shares of the company’s stock valued at $27,000 after purchasing an additional 1,088 shares in the last quarter. State of Wyoming purchased a new position in shares of Tyra Biosciences during the 2nd quarter worth approximately $76,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Tyra Biosciences during the 3rd quarter worth approximately $67,000. Canada Pension Plan Investment Board acquired a new position in shares of Tyra Biosciences during the 2nd quarter worth approximately $230,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Tyra Biosciences during the 2nd quarter worth approximately $237,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Key Stories Impacting Tyra Biosciences

These are some of the TYRA stories that stood out recently:

• Positive Sentiment: Wedbush raised its price target to $57 from $53 and maintained an Outperform rating, signaling increased analyst confidence. Wedbush price target update
• Neutral Sentiment: Tyra reported initial Phase 2 SURF302 results for dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer; the provided report does not detail the results, limiting assessment of their clinical significance. Tyra Q3 results and highlights
• Neutral Sentiment: HC Wainwright lowered its price target to $27 from $29 but kept a Buy rating, a mixed signal on the stock’s prospects. HC Wainwright recommendations

About Tyra Biosciences

Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.